Moderna (MRNA)
(Delayed Data from NSDQ)
$125.00 USD
-0.59 (-0.47%)
Updated May 3, 2024 04:00 PM ET
After-Market: $125.10 +0.10 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$125.00 USD
-0.59 (-0.47%)
Updated May 3, 2024 04:00 PM ET
After-Market: $125.10 +0.10 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Gritstone (GRTS) Inks Deal With CEPI for Coronavirus Vaccine
by Zacks Equity Research
Gritstone (GRTS) signs an agreement with CEPI for up to $20.6 million to develop its COVID-19 vaccine program with an initial focus in South Africa. Shares rise.
Mei (MEIP) Begins Phase III Study for B-Cell Malignancies
by Zacks Equity Research
Mei Pharma (MEIP) doses first patient in phase III study to evaluate zandelisib plus rituximab in follicular lymphoma or marginal zone lymphoma.
Aurinia (AUPH) Adds Two Candidates, Boosts Immunology Pipeline
by Zacks Equity Research
Aurinia (AUPH) acquires two pre-clinical, novel pipeline programs for the treatment of rare autoimmune, fibrotic and kidney diseases. Yet, the stock price declines.
Moderna (MRNA) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Pfizer (PFE)/BioNTech Give First COVID Jab Booster Data to FDA
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) booster dose of COVID-19 vaccine elicited antibody levels that were much higher than that seen after the two-dose primary schedule.
Moderna (MRNA) Begins Rare Disease Study, Inks Supply Agreement
by Zacks Equity Research
Moderna (MRNA) doses first patient in phase I/II study with mRNA-3705 for the treatment of a rare multi-organ disorder. The company also revises the supply agreement with the Canadian Government for its COVID vaccine.
5 Stocks Leading the Rally in S&P 500 ETF
by Sweta Killa
The S&P 500 Index has been hitting a series of record highs, braving a myriad of hurdles.
Sesen's (SESN) Bladder Cancer Drug Vicineum Gets CRL From FDA
by Zacks Equity Research
Sesen's (SESN) biologics license application filed for Vicineum to treat BCG-unresponsive non-muscle invasive bladder cancer fails to secure approval. The stock declines resultantly.
Pfizer's (PFE) Tick-Borne Encephalitis Vaccine Gets FDA Nod
by Zacks Equity Research
Pfizer's (PFE) tick-borne encephalitis vaccine that is already approved in Europe and other countries gains FDA approval.
Moderna (MRNA) Gets EUA for Third Dose of COVID-19 Vaccine
by Zacks Equity Research
The FDA authorizes third dose of Moderna's (MRNA) COVID-19 vaccine for use in immunocompromised adults.
The Zacks Analyst Blog Highlights: Chewy, Pinterest, Schlumberger, EOG Resources and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chewy, Pinterest, Schlumberger, EOG Resources and Moderna
Moderna ETFs to Shine Bright on Booster Update, New Study Data
by Sweta Jaiswal, FRM
Moderna is expected to gain on approval for booster shots and new positive data on its COVID-19 vaccine.
6 Stocks to Buy on the Dip With Strong Upside Left for 2021
by Nalak Das
We have narrowed down our search to six large-cap stocks that have attained a 52-week high this year but are currently trading at a sharp discount. These are: CHWY, PINS, ROKU, SLB, EOG and MRNA.
mRNA COVID-19 Vaccine Makers Lose Steam After Strong Rally
by Indrajit Bandyopadhyay
Stocks of mRNA-based COVID-19 vaccine makers, MRNA, PFE and BNTX fall for two consecutive days on bearish sentiments after a strong rally as well as probable side-effects of their vaccines.
Do Options Traders Know Something About Moderna (MRNA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Perrigo (PRGO) Q2 Earnings Lag, Sales Hurt by Weak Cold Season
by Zacks Equity Research
Perrigo (PRGO) reports dismal second-quarter 2021 results. Stock down.
Is Moderna (MRNA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MRNA) Outperforming Other Medical Stocks This Year?
Is iShares MSCI USA Equal Weighted ETF (EUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for EUSA
Novavax's (NVAX) Q2 Loss Widens, Revenues Miss, Shares Down
by Zacks Equity Research
Novavax (NVAX) reports wider-than-expected loss in the second quarter of 2021 while revenues also miss estimates. Shares down in after-hours trading.
Stock Market News for Aug 6, 2021
by Zacks Equity Research
Benchmarks ended in the green on Thursday, as investors accessed positive weekly jobless claims data and awaited the monthly jobs report on Aug 6.
Bull of the Day: Vertex Pharmaceuticals (VRTX)
by Kevin Cook
Scientific innovation in the treatment of cystic fibrosis bolsters success and pipeline confidence
Moderna (MRNA) Q2 Earnings Top, COVID-19 Vaccine Brings $4.2B
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine continues to enjoy robust demand. The company delivered 199 million doses of its COVID-19 vaccine during the second quarter.
Stock Market News for Aug 5, 2021
by Zacks Equity Research
The Dow and the S&P 500 closed in the red on Wednesday weighed by a lower-than-expected private-sector jobs report and Fed's Vice Chairman Richard Clarida's comment on higher interest rates in 2023 given the current path of economic recovery.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Moderna (MRNA) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 7.49% and 1.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?